Login to Your Account



Inspire Comes Up Short In Phase III Study; Stock Falls 73 Percent

By Kim Coghill


Thursday, January 17, 2002
Inspire Pharmaceuticals Inc. said it’s not likely that the first Phase III trial of its lead product for dry eye will reach its endpoints. The negative news sent Inspire’s stock tumbling 73 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription